Basic principles for the treatment of chronic rhinosinusitis with nasal polyps

Introduction. Chronic rhinosinusitis with nasal polyps (CRSwNP) is based on a chronic inflammatory hyperplastic process in the mucosa membrane of the nasal cavity and paranasal sinuses (SNPs). According to the consensus on the biological treatment of CRSwNP with or without asthma, which is one of the latest consensus documents of the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), which was published in December 2019, the need for surgical treatment or systemic administration of corticosteroids due to the active nasal polyps growth are conditional signs for the decompensation of clinical control. Currently, the basic treatment for patients with CRSwNP is the long-term use of intranasal corticosteroids (INCS), which leads to an improvement in the quality of life, while minimizing the risk of exacerbations and complications.

Research purpose. To evaluate the effectiveness of the basic therapy of intranasal glucocorticosteroid mometasone furoate for different phenotypes of CRSwNP.

Methods. All patients with recurrent CRSwNP were divided into 3 equal phenotypic groups of 40 people each: group 1 – CRSwNP without asthma and respiratory allergies, group 2 – CRSwNP + atopy, group 3 – CRSwNP + non-allergic asthma. The observation period was 3 years.

Results. Using the algorithm of stepwise therapy of CRSwNP, dynamic monitoring of these patients by an ENT and an allergistimmunologist, basic therapy with corticosteroids with constant treatment correction once every 3 months, it was possible to stabilize the inflammatory process throughout the respiratory tract and reduce the need for surgical treatment.

Conclusion. With CRSwNP, long-term use of Mometasone furoate INCS is the main drug of basic therapy to minimize the recurrence of nasal polyp growth and is accompanied by clinical efficacy and the absence of adverse side effects.

1. Ozturan A., Eyigor H., Eyigor M., Osma U., Yilmaz M.D., Selcuk O.T., Renda L., Gultekin M. The role of IL-25 and IL-33 in chronic rhinosinusitis with or without nasal polyps. Eur Arch Otorhinolaryngol. 2017;274(1):283–288. doi: 10.1007/s00405-016-4260-6.

2. Wu D., Bleier B.S., Li L., Zhan X., Zhang L., Lv Q., Wang J., Wei Y. Clinical phenotypes of nasal polyps and comorbid asthma based on cluster analysis of disease history. J Allergy Clin Immunol Pract. 2018;6(4):1297–1305. doi: 10.1016/j.jaip.2017.09.020.

3. Orlandi R.R., Kingdom T.T., Hwang P.H., Smith T.L., Alt J.A., Baroody F.M. et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(Suppl 1):S22–S209. doi: 10.1002/alr.21695.

4. Fokkens W.J., Lund V., Bachert C., Mullol J., Bjermer L., Bousquet J. et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312–2319. doi: 10.1111/all.13875.

5. Passali D., Spinosi M.C., Crisanti A., Bellussi L.M. Mometasone furoate nasal spray: a systematic review. Multidiscip Respir Med. 2016;11:18. doi: 10.1186/s40248-016-0054-3.

6. Svistushkin V.M., Sinkov E.V. Effective control of symptoms at patients with allergic rhinitis. Meditsinskiy sovet = Medical Council. 2019;(12):54–56. (In Russ.) doi: 10.21518/2079-701X-2019-12-54-56.

7. Samoliński B., Nowicka A., Wojas O., Lipiec A., Krzych-Fałta E., Tomaszewska A. Intranasal glucocorticosteroids – not only in allergic rhinitis In the 40th anniversary of intranasal glucocorticosteroids’ introduction. Otolaryngol Pol. 2014;68(2):51–64. doi: 10.1016/j.otpol.2013.12.003.

8. Ushkalova E.A. Intranasal corticosteroids in the treatment of allergic rhinitis. Trudnyy patsiyent = Difficult Patient. 2005;3(6):18–23. (In Russ.) Available at: http://t-pacient.ru/articles/6133.

9. Grzanka A., Misiołek M., Golusiński W., Jarząb J. Molecular mechanisms of glucocorticoids action: implications for treatment of rhinosinusitis and nasal polyposis. Eur Arch Otorhinolaryngol. 2011;268(2):247–253. doi: 10.1007/s00405-010-1330-z.

10. Pujols L., Mullol J., Picado C. Alpha and beta glucocorticoid receptors: Relevance in airway diseases. Curr Allergy Asthma Rep. 2007;7:93–99. doi: 10.1007/s11882-007-0005-3.

11. Pujols L., Alobid I., Benitez P., Martinez-Antón A., Roca-Ferrer J., Fokkens W.J. et al. Regulation of glucocorticoid receptor in nasal polyps by systemic and intranasal glucocorticoids. Allergy. 2008;63(10):1377–1386. doi: 10.1111/j.1398-9995.2008.01745.x.

12. Scadding G.K., Durham S.R., Mirakian R., Jones N.S., Drake-Lee A.B., Ryan D. et al. BSACI guidelines for the management of rhinosinusitis and nasal polyposis. Clin Exp Allergy. 2008;38(2):260–275. doi: 10.1111/j.1365-2222.2007.02889.x.

13. Fokkens W.J., Lund V.J., Hopkins C., Hellings P.W., Kern R., Reitsma S. et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1–464. doi: 10.4193/Rhin20.600.

14. Savlevich E.L., Dyneva M.E., Gaganov L.E., Egorov V.I., Gerasimov A.N., Kurbacheva O.M. Diagnostic and treatment algorithm for different phenotypes of chronic rhinosinusitis with nasal polyps. Rossiyskiy allergologicheskiy zhurnal = Russian Journal of Allergy. 2019;16(2):50–60. (In Russ.) doi: 10.36691/RJA1198.

15. Egorov V.I., Ryazantsev S.V., Karneeva O.V., Kazanova A.V., Maksimova E.A. Polypoid rhinosinusitis: clinical guidelines. Мoscow; 2016. 21 p. (In Russ.) Available at: http://glav-otolar.ru/assets/images/docs/clinical-recomendations/%D0%9A%D0%A0316%20%20Polipoznyj%20rinosinusit1.pdf.

16. Verkerk M.M., Bhatia D., Rimmer J., Earls P., Sacks R., Harvey R.J. Intranasal steroids and the myth of mucosal atrophy: a systematic review of original histological assessments. Am J Rhinol Allergy. 2015;29(1):3–18. doi: 10.2500/ajra.2015.29.4111.

17. Kozlov V.S., Savlevich E.L. Chronic rhinosinusitis with nasal polyps. The recent trend in the studies of the pathogenesis, diagnosis and treatment of this disease. Vestnik otorinolaringologii = Bulletin of Otorhinolaryngology. 2015;80(4):107–111. (In Russ.) doi: 10.17116/otorino201580495-99.

18. Savlevich E.L., Egorov V.I., Shachnev K.N., Tatarenko N.G. The analysis of polypous rhinosinusitis treatment regimens in the Russian Federation. Rossiiskaya otorinolaringologiya = Russian Otorhinolaryngology. 2019;18(1):124–134. (In Russ.) doi: 10.18692/1810-4800-2019-1-124-134.

19. Shakhova E.G. The role of topical glucocorticoids in the treatment of rhinosinusitis. Vestnik otorinolaringologii = Bulletin of Otorhinolaryngology. 2017;82(2):70–73. (In Russ.) doi: 10.17116/otorino201782270-73.